Research programme: pain therapeutics - AstraZenecaAlternative Names: AZ 09; AZ 11760788; AZ 12048189; AZ 12099548; AZ 1297442; AZ 599; AZD 7903; AZD 9335
Latest Information Update: 06 Sep 2012
At a glance
- Originator AstraZeneca
- Class 3-ring heterocyclic compounds; Indoles; Isoxazoles; Pyridines; Sulfonamides
- Mechanism of Action Bradykinin B2 receptor antagonists; Cannabinoid receptor CB1 agonists; Nav1.7-voltage-gated-sodium-channel-inhibitors; Sodium channel antagonists; TRPV1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Inflammatory pain; Neuropathic pain
- Discontinued Gastro-oesophageal reflux